Open up the floodgates: Gilead's hep C wonder-cocktail, Harvoni, has won approval in Europe.
AbbVie is heralding positive new data on its hepatitis C cocktail, touting the treatment's benefit in some tough-to-treat patients as it prepares for a head-to-head competition with market leader Gilead Sciences.
After sending out signals that it might be running into trouble with a short-duration study of a new triple combination drug for its hepatitis C regimen, Merck investigators hailed the clear success of an 8-week test but confirmed analysts' fears in a batch of 4-week data released at the meeting of the American Association for the Study of Liver Diseases.
Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.
Anyone following the hepatitis C drug market knows that Express Scripts CMO Steve Miller has a strong point of view.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
So you thought Gilead's Sovaldi was expensive? Get ready for Harvoni, the company's all-oral hep C combo regimen that won FDA approval on Friday. Cost? $94,500 for a 12-week course of treatment.
Gilead Sciences picked up a much-anticipated FDA approval for Harvoni, a combination therapy for hepatitis C that promises to cure the majority of patients without the need for painful injections that have plagued patients for years.
Bristol-Myers Squibb is pulling out of one key race in the global scramble to develop new blockbuster hepatitis C cocktails.